12A-1100922
PCT and TW application pending
The treatment of spinal cord injury (SCI) is an unmet medical need. Equilibrative nucleoside transporter-1 (Ent1) is important for controlling extracellular level of adenosine, a modulator for immune and neuronal functions. In this invention, we found a new drug candidate with the potential for the treatment of SCI.
Mice were subjected to SCI on T10 dorsal portion by contusion method to cause a complete paralysis of hindlimbs. The new compound evaluated in terms of Basso Mouse scale (BMS), gait analysis, and neuroinflammation on 14 days post-injury.
As a result, it improved motor function and reduced neuroinflammation at the perilesional site of mice with SCI, suggesting that the new compound is a potential candidate for SCI treatment.
- The treatment of spinal cord injury is an unmet medical need
- Improves motor function in spinal cord injury
- Reduces neuroinflammation in spinal cord injury
Yijuang Chern, Chun-Jung Lin, Kuan-Yu Chen and Jim-Min Fang
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

METHOD OF TREATING SPINAL CORD INJURY AND COMPOSITION FOR USE THEREIN